SOLARA Solara Active Pharma Sciences Q1 FY27 results (Apr–Jun 2026) and concall
Solara Active Pharma Sciences Limited delivered a strong Q1 FY27, achieving its highest EBITDA and PAT in 18 quarters, driven by robust performance in its base business. The company significantly reduced its net debt and maintained focus on operational efficiency and profitable growth. However, the Ibuprofen business continues to face profitability challenges amidst volatile raw material prices and supply chain disruptions.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q1 FY27: revenue up 19.7%, net profit up 45.5% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|
| Revenue | 300 | 273 | 319 | 314 | 349 +16% | 387 +42% | 382 +20% |
| EBITDA | 58 | 45 | 57 | 35 | 37 −36% | 58 +29% | 62 +9% |
| Net profit | 8 | -2 | 11 | -10 | -17 −312% | 10 +600% | 16 +45% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
